Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 209

1.

Advances in antiplatelet technologies to improve cardiovascular disease morbidity and mortality: a review of ticagrelor.

Davis EM, Knezevich JT, Teply RM.

Clin Pharmacol. 2013 Apr 19;5:67-83. doi: 10.2147/CPAA.S41859. Print 2013.

2.

[Antiplatelet drugs].

Nishikawa M.

Nihon Rinsho. 2014 Jul;72(7):1248-53. Review. Japanese.

PMID:
25163316
3.

Updates in antiplatelet agents used in cardiovascular diseases.

Cheng JW.

J Cardiovasc Pharmacol Ther. 2013 Nov;18(6):514-24. doi: 10.1177/1074248413499971. Review.

PMID:
24213473
4.

Prasugrel (Efient®) with percutaneous coronary intervention for treating acute coronary syndromes (review of TA182): systematic review and economic analysis.

Greenhalgh J, Bagust A, Boland A, Dwan K, Beale S, Fleeman N, McEntee J, Dundar Y, Richardson M, Fisher M.

Health Technol Assess. 2015 Apr;19(29):1-130. doi: 10.3310/hta19290. Review.

5.

Tailored antiplatelet therapy to improve prognosis in patients exhibiting clopidogrel low-response prior to percutaneous coronary intervention for stable angina or non-ST elevation acute coronary syndrome.

Paarup Dridi N, Johansson PI, Lønborg JT, Clemmensen P, Radu MD, Qayyum A, Pedersen F, Kollslid R, Helqvist S, Saunamäki K, Kelbæk H, Jørgensen E, Engstrøm T, Holmvang L.

Platelets. 2015;26(6):521-9. doi: 10.3109/09537104.2014.948837. Epub 2014 Aug 28.

PMID:
25166751
6.

Evolving pattern of platelet P2Y12 inhibition in patients with acute coronary syndromes.

Joshi RR, Hossain R, Morton AC, Ecob R, Judge HM, Wales C, Walker JV, Karunakaran A, Storey RF.

Platelets. 2014;25(6):416-22. doi: 10.3109/09537104.2013.836175. Epub 2013 Oct 10.

PMID:
24111601
7.
8.

Current Status of Antiplatelet Therapy in Acute Coronary Syndrome.

Dash D.

Cardiovasc Hematol Agents Med Chem. 2015;13(1):40-9. Review.

PMID:
26245659
9.
10.

Ticagrelor or prasugrel versus clopidogrel in elderly patients with an acute coronary syndrome: Optimization of antiplatelet treatment in patients 70 years and older--rationale and design of the POPular AGE study.

Qaderdan K, Ishak M, Heestermans AA, de Vrey E, Jukema JW, Voskuil M, de Boer MJ, van't Hof AW, Groenemeijer BE, Vos GJ, Janssen PW, Bergmeijer TO, Kelder JC, Deneer VH, ten Berg JM.

Am Heart J. 2015 Nov;170(5):981-985.e1. doi: 10.1016/j.ahj.2015.07.030. Epub 2015 Aug 4.

PMID:
26542508
11.

Cost-effectiveness of universal and platelet reactivity assay-driven antiplatelet therapy in acute coronary syndrome.

Coleman CI, Limone BL.

Am J Cardiol. 2013 Aug 1;112(3):355-62. doi: 10.1016/j.amjcard.2013.03.036. Epub 2013 Apr 27.

PMID:
23631863
13.

Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study.

Alexopoulos D, Galati A, Xanthopoulou I, Mavronasiou E, Kassimis G, Theodoropoulos KC, Makris G, Damelou A, Tsigkas G, Hahalis G, Davlouros P.

J Am Coll Cardiol. 2012 Jul 17;60(3):193-9. doi: 10.1016/j.jacc.2012.03.050.

14.

MULTInational non-interventional study of patients with ST-segment elevation myocardial infarction treated with PRimary Angioplasty and Concomitant use of upstream antiplatelet therapy with prasugrel or clopidogrel--the European MULTIPRAC Registry.

Clemmensen P, Grieco N, Ince H, Danchin N, Goedicke J, Ramos Y, Schmitt J, Goldstein P; MULTIPRAC study investigators.

Eur Heart J Acute Cardiovasc Care. 2015 Jun;4(3):220-9. doi: 10.1177/2048872614547449. Epub 2014 Sep 2.

PMID:
25182465
15.

[Impact of novel P2Y12 receptor inhibitors on platelet reactivity in acute coronary syndrome patients undergoing percutaneous coronary intervention].

Chong Tou TJ, Liu PM, Wang JF, Sio Cham ZC, O U YF, Lei Sio ZW, Lei Put PZ, Lei Sok SM, Zhou SX, Wu W.

Zhonghua Xin Xue Guan Bing Za Zhi. 2016 Feb;44(2):138-43. doi: 10.3760/cma.j.issn.0253-3758.2016.02.011. Chinese.

PMID:
26926507
16.

Republished: Antiplatelet therapy for secondary prevention of coronary artery disease.

Pilgrim T, Windecker S.

Postgrad Med J. 2015 May;91(1075):284-90. doi: 10.1136/postgradmedj-2013-305399rep.

PMID:
25976494
17.

Did Prasugrel and Ticagrelor Offer the Same Benefit in Patients with Acute Coronary Syndromes after Percutaneous Coronary Interventions Compared to Clopidogrel? Insights from Randomized Clinical Trials, Registries and Meta-analysis.

Rodriguez AE, Rodriguez-Granillo AM, Ascarrunz SD, Peralta-Bazan F, Cho MY.

Curr Pharm Des. 2018 Jan 8. doi: 10.2174/1381612824666180108121834. [Epub ahead of print]

PMID:
29308737
18.

Ticagrelor: a novel reversible oral antiplatelet agent.

Nawarskas JJ, Clark SM.

Cardiol Rev. 2011 Mar-Apr;19(2):95-100. doi: 10.1097/CRD.0b013e3182099d86. Review.

PMID:
21285670
19.

Pharmacodynamic Comparison of Prasugrel Versus Ticagrelor in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The OPTIMUS (Optimizing Antiplatelet Therapy in Diabetes Mellitus)-4 Study.

Franchi F, Rollini F, Aggarwal N, Hu J, Kureti M, Durairaj A, Duarte VE, Cho JR, Been L, Zenni MM, Bass TA, Angiolillo DJ.

Circulation. 2016 Sep 13;134(11):780-92. doi: 10.1161/CIRCULATIONAHA.116.023402. Epub 2016 Aug 24.

20.

Ticagrelor, prasugrel, or clopidogrel in ST-segment elevation myocardial infarction: which one to choose?

Guimarães PO, Tricoci P.

Expert Opin Pharmacother. 2015;16(13):1983-95. doi: 10.1517/14656566.2015.1074180. Epub 2015 Jul 29. Review.

PMID:
26224244

Supplemental Content

Support Center